Recombinant Human AIP, His-tagged

• Cat.No.: AIP-3595H
• Product Overview: Recombinant human AIP protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques (1-330 aa).

Specification

• Cat. No.: AIP-3595H
• Description: Aryl hydrocarbon receptor (AHR) interacting protein, also known as AIP, may play a positive role in AHR-mediated (aromatic hydrocarbon receptor) signaling, possibly by influencing its receptivity for ligand and/or its nuclear targeting. It is a Cellular negative regulator of the hepatitis B virus (HBV) X protein. Also, AIP is a ubiquitously expressed protein, binds to HSP 90 and AHR through a highly conserved carboxy-terminal tetraticopeptide repeat domain.
• Form: Liquid. In 20mM Tris-HCl buffer (pH 8.0) containing 1mM DTT, 10% glycerol
• Molecular Weight: 39.8 kDa (350aa), confirmed by MALDI-TOF
• Purity: > 90% by SDS - PAGE
• Concentration: 1 mg/ml (determined by Bradford assay)
• Sequences of amino acids: MGSSHHHHHH SSGLVPRGSH MADIIARLRE DGIQKRVIQE GRGELPDFQD GTKATFHYRT LHSDDEGTVL DDSRARGKPM ELIIGKKFKL PVWETIVCTM REGEIAQFLC DIKHVVLYPL VAKSLRNIAV GKDPLEGQRH CCGVAQMREH SSLGHADLDA LQQNPQPLIF HMEMLKVESP GTYQQDPWAM TDEEKAKAVP LIHQEGNRLY REGHVKEAAA KYYDAIACLK NLQMKEQPGS PEWIQLDKQI TPLLLNYCQC KLVVEEYYEV LDHCSSILNK YDDNVKAYFK RGKAHAAVWN AQEAQADFAK VLELDPALAP VVSRELRALE ARIRQKDEED KARFRGIFSH
• Storage: Can be stored at +4°C short term (1-2 weeks). For long term storage, aliquot and store at -20°C or -70°C. Avoid repeated freezing and thawing cycles.

Gene Information

• Gene Name: AIP aryl hydrocarbon receptor interacting protein [ Homo sapiens ]
• Official Symbol: AIP
• Synonyms: AIP; ARA9; XAP2; FKBP16; FKBP37; SMTPHN; aryl hydrocarbon receptor interacting protein; XAP-2; AH receptor-interacting protein; OTTHUMP00000236411; OTTHUMP00000236412; HBV-X associated protein; immunophilin homolog ARA9; HBV X-associated protein 2; aryl hydrocarbon receptor-interacting protein; aryl-hydrocarbon receptor interacting protein; aryl-hydrocarbon receptor-interacting protein; Aryl-hydrocarbon receptor-interacting protein; Immunophilin homolog ARA9
• Gene ID: 9049
• mRNA Refseq: NM_003977
• Protein Refseq: NP_003968
• MIM: 605555
• UniProt ID: O00170
• Chromosome Location: 11q13.3
• Function: protein binding; signal transducer activity; transcription coactivator activity; transcription factor binding; unfolded protein binding

Reviews

11/20/2018

Their expertise and commitment to excellence guarantee swift resolution of any issues, facilitating seamless progress in my research endeavors.

12/29/2016

By harnessing the power of the AIP protein and leveraging the manufacturer's exceptional technical assistance, my experimental obstacles can be effortlessly overcome.

12/02/2015

With an insight into the complex mechanisms governed by AIP, this protein empowers me to unravel mysteries in my field and expands the horizon of possibilities in scientific advancement.

Q&As

Is there any dietary link to AIP protein?

While there is no direct dietary link to the AIP protein, there are some dietary protocols that are known as the Autoimmune Protocol (AIP) that are designed to reduce inflammation and balance the immune system. The AIP diet is a restrictive form of the paleo diet that eliminates foods that are known to commonly cause food allergies or sensitivities, such as gluten, dairy, grains, legumes, and nightshade vegetables. The purpose of the AIP diet is to give the body a chance to heal and reduce inflammation, which may help with autoimmune conditions that are linked to AIP mutations.

Is there any known risk associated with low levels of AIP protein?

Reduced expression of the AIP protein has been associated with increased risk of cancer, particularly pituitary adenomas and other endocrine tumors. It has also been suggested that reduced AIP expression may play a role in the development and progression of other types of cancer. However, more research is needed to understand the exact mechanisms involved and how the AIP protein can be targeted for cancer prevention or treatment.

Are there any treatments for AIP-related conditions?

Treatment for AIP-related conditions depends on the specific condition and the individual patient's needs. For pituitary adenomas or other endocrine tumors associated with AIP mutations, treatment may involve surgery, radiation therapy, chemotherapy, or medication to control hormone secretion. Patients with FIPA may undergo regular monitoring and screening to detect early signs of tumors. Hormone replacement therapy may also be necessary to manage hormone deficiencies in patients with pituitary tumors.

Can individuals with AIP mutations have children?

Yes, individuals with AIP mutations can have children if they wish to do so. However, there is a 50% chance that the mutation will be passed on to each child. Genetic counseling may be recommended for individuals with AIP mutations who are considering having children to discuss their options and the risks involved.

Is there a cure for AIP-related conditions?

Currently, there is no cure for AIP-related conditions. Treatment is focused on managing symptoms, controlling hormone secretion, and removing or shrinking tumors, if necessary. Research is ongoing to identify new treatments and therapies for these conditions.

How is the AIP protein used in diagnosis and treatment of diseases?

In patients with FIPA, genetic testing for mutations in the AIP gene can aid in diagnosis and guide treatment. In oncology, the AIP protein has been suggested as a potential biomarker for cancer prognosis and treatment response. Additionally, researchers are investigating the use of the AIP protein as a therapeutic target for cancer treatment.

How common are AIP mutations?

AIP mutations are rare and only account for a small percentage of cases of pituitary adenomas and other endocrine tumors. The exact prevalence of AIP mutations in the general population is not known, but estimates suggest that they may be found in less than 1% of people with pituitary adenomas.

Can AIP mutations cause symptoms other than those related to endocrine tumors?

Yes, although AIP mutations are primarily associated with pituitary adenomas and other endocrine tumors, some individuals with AIP mutations may experience other symptoms, including headaches, fatigue, muscle weakness, joint pain, and gastrointestinal issues. These symptoms are not directly related to AIP mutations but may be associated with underlying health conditions or other factors.

What are some potential future directions for research on the AIP protein?

Future research on the AIP protein may focus on understanding its role in cancer development and progression, as well as potential therapeutic targets for cancer treatment. Other areas of interest include the role of the AIP protein in the regulation of pituitary hormone secretion, and the potential use of the AIP protein as a diagnostic biomarker or therapeutic target for various health conditions associated with AIP mutations.

How is an AIP mutation diagnosed?

AIP mutations can be identified through genetic testing, which involves analyzing a person's DNA for known mutations in the AIP gene. Genetic testing may be recommended for individuals with a personal or family history of pituitary adenomas, other endocrine tumors, or other conditions associated with AIP mutations. Testing may also be recommended for individuals who have symptoms or signs of a hormone imbalance or other tumor-related issues.

What are some other health conditions associated with AIP protein mutations?

In addition to FIPA, mutations in the AIP gene have been associated with other health conditions such as acromegaly, gigantism, and Cushing's disease. These conditions are characterized by hormonal imbalances that result in abnormal growth, particularly in the pituitary gland. AIP mutations have also been linked to increased risk of breast cancer.

Can AIP mutations be inherited?

Yes, AIP mutations can be inherited in an autosomal dominant manner, meaning that only one copy of the mutated gene is needed to cause the condition. This means that a person with an AIP mutation has a 50% chance of passing the mutation on to each of their children.

Are there any preventative measures for AIP-related conditions?

Currently, there are no known preventative measures for AIP-related conditions. However, genetic testing can be a useful tool for identifying individuals who may be at increased risk for developing these conditions. Regular monitoring and screening may be recommended for individuals with AIP mutations or a family history of pituitary adenomas or other endocrine tumors.